• 1
    Bostwick DG, Meiers I. Prostate biopsy and optimization of cancer yield. Eur Urol 2006; 49: 415417
  • 2
    Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212236
  • 3
    Lin YK, Gettle L, Raman JD. Variable prostate-specific antigen management patterns by nonurologist providers at a tertiary care medical center. Urology 2011; 78: 244248
  • 4
    Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl. 2): S144157
  • 5
    Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 2003; 52: 10051010
  • 6
    Akduman B, Akduman D, Tokgöz H et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 2011; 78: 250255
  • 7
    Feliciano J, Teper E, Ferrandino M et al. The incidence of fluoroquinolone resistant infections after prostate biopsy – are fluoroquinolones still effective prophylaxis? J Urol 2008; 179: 952955
  • 8
    Erol H, Beder N, Calişkan T et al. Can the effect of antibiotherapy and anti- inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? Urol Int 2006; 76: 2026
  • 9
    Kaygisiz O, Uğurlu O, Koşan M et al. Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10 ng/ml. Prostate Cancer Prostatic Dis 2006; 9: 235238
  • 10
    Serretta V, Catanese A, Daricello G et al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer Prostatic Dis 2008; 11: 148152
  • 11
    Shtricker A, Shefi S, Ringel A et al. PSA levels of 4.0–10 ng/mL and negative digital rectal examination. Antibiotic therapy versus immediate prostate biopsy. Int Braz J Urol 2009; 35: 551558
  • 12
    Baltaci S, Süer E, Haliloğlu AH et al. Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. J Urol 2009; 181: 128132
  • 13
    Eastham JA, Riedel E, Scardino PT et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289: 26952700
  • 14
    Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin Trials 1988; 9: 327344
  • 15
    Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989; 33: 465
  • 16
    Ornstein DK, Smith DS, Rao GS et al. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997; 157: 21792182
  • 17
    Nadler RB, Humphrey PA, Smith DS et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407413
  • 18
    Schaeffer AJ, Wu SC, Tennenberg AM et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol 2005; 174: 161164
  • 19
    Stopiglia RM, Ferreira U, Silva MM Jr et al. Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial. J Urol 2010; 183: 940944
  • 20
    Kyung YS, Lee HC, Kim HJ. Changes in serum prostate-specific antigen after treatment with antibiotics in patients with lower urinary tract symptoms/benign prostatic hyperplasia with prostatitis. Int Neurourol J 2010; 14: 100104
  • 21
    Loeb S, Gashti SN, Catalona WJ. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol Oncol 2009; 27: 6466